PNC Financial Services Group
RLMD icon

PNC Financial Services Group’s Relmada Therapeutics RLMD Stock Holding History

PNC Financial Services Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-98
Closed -$241 – 4726
2023
Q2 		$241 Sell
98
-1,762
-95% -$4.87K ﹤0.01% 4654
2023
Q1 		$4.2K Buy
1,860
+1,586
+579% +$5.47K ﹤0.01% 4095
2022
Q4 		$956 Buy
274
+197
+256% +$1.73K ﹤0.01% 4418
2022
Q3 		$3K Buy
77
+64
+492% +$1.77K ﹤0.01% 4104
2022
Q2 		$0 Hold
13
– – ﹤0.01% 4677
2022
Q1 		$0 Buy
+13
New +$269 ﹤0.01% 4676

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PNC Financial Services Group's RLMD Position: Q3 2023 in Review

PNC Financial Services Group sold out of Relmada Therapeutics (RLMD) in Q3 2023, closing a stake of 98 shares — an estimated $241 sold.

PNC Financial Services Group first reported a position in RLMD in Q1 2022 and held it in 6 quarters. The position peaked at $4.2K in Q1 2023. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2023.

  • PNC Financial Services Group reported no remaining Relmada Therapeutics position as of Q3 2023 after selling out during the quarter.
  • PNC Financial Services Group sold 98 Relmada Therapeutics shares in Q3 2023, an estimated $241.
  • PNC Financial Services Group first reported a position in Relmada Therapeutics in Q1 2022 and held it in 6 quarters.
  • PNC Financial Services Group's Relmada Therapeutics position peaked at $4.2K in Q1 2023.
  • 87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2023.

Based on PNC Financial Services Group's 13F filing for Q3 2023, filed 13 Nov 2023.